🇺🇸 SAR231893 in United States

17 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 17

Most-reported reactions

1. Eosinophilia — 3 reports (17.65%)
2. Anaphylactic Reaction — 2 reports (11.76%)
3. Eczema — 2 reports (11.76%)
4. Erythema Nodosum — 2 reports (11.76%)
5. Pneumonia — 2 reports (11.76%)
6. Pruritus — 2 reports (11.76%)
7. Abortion Spontaneous — 1 report (5.88%)
8. Adenocarcinoma Gastric — 1 report (5.88%)
9. Amnesia — 1 report (5.88%)
10. Angina Pectoris — 1 report (5.88%)

Source database →

Frequently asked questions

Is SAR231893 approved in United States?

SAR231893 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for SAR231893 in United States?

Sanofi is the originator. The local marketing authorisation holder may differ — check the official source linked above.